SRRM2 antisense RNA 1 (SRRM2-AS1)

SRRM2 antisense RNA 1 (SRRM2-AS1) is a long non-coding RNA predominantly located in the nucleus, highly expressed in multiple cancer tissues including nasopharyngeal carcinoma and ovarian cancer[2][4]. It regulates cancer cell proliferation, differentiation, invasion, and angiogenesis, primarily through modulation of gene expression (notably suppressing MYLK and affecting cGMP-PKG signaling in nasopharyngeal carcinoma)[2]. Experimental silencing of SRRM2-AS1 induces cell cycle arrest and apoptosis and reduces angiogenesis by upregulating pro-apoptotic markers and decreasing proliferation and angiogenesis markers[2]. In ovarian cancer, its expression correlates with microtubule-based movement, cilium movement, and immune cell signaling pathways, playing a proposed role in the pathogenesis and maintaining malignant phenotypes[4]. SRRM2-AS1 shows potential as a diagnostic biomarker for ovarian cancer and may have therapeutic interest as a regulator of oncogenic processes, though it is not a direct target of any approved drugs.

Other names

CTD-2270P14.3SRRM2 antisense RNA 1 (non-protein coding)SRRM2-AS1

Not applicable (no direct drug-target relationships identified). Silencing or knockdown leads to increased MYLK expression, activation of cGMP-PKG pathway, upregulation of pro-apoptotic markers (Bax, Caspase 3), and reduction of proliferation/angiogenesis markers. Regulation of downstream gene expression and cell signaling pathways.